Clovis ups public offering to $240m
This article was originally published in Scrip
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has announced a public offering to raise $170m on the back of the company's huge share price rise following its presentation at the American Society of Clinical Oncology annual meeting in Chicago 3 June.